Skip to main content

Table 1 Comparison between control group and TPE group regarding demographics, clinical, and laboratory criteria

From: Determinants of quality of life changes with plasmapheresis in patients with myasthenia gravis

  Control group TPE group Test value P value Sig
No. =17 No. =81
Sex Females 10 (58.8%) 58 (71.6%) 1.081b 0.299 NS
Males 7 (41.2%) 23 (28.4%)
Age Mean ± SD 35.29 ± 11.65 35.69± 12.46 −0.121 0.904 NS
Range 18-60 18-60
Duration by month Mean ± SD 42.47 ± 18.19 36.59 ± 20.18 1.109a 0.270 NS
Range 18-80 12-96
AchR antibodies Negative 3 (17.6%) 16 (19.8%) 0.040b 0.842 NS
Positive 14 (82.4%) 65 (80.2%)
AchR titer Median (IQR) 8 (6.7-9.2) 13.2 (9.2-19) 3.091 0.002 HS
Range 4.3-16.3 4.6-80.6
Thymectomy Negative 7 (41.2%) 29 (35.8%) 0.175 0.676 NS
Positive 10 (58.8%) 52 (64.2%)
Thymus gland Normal 5 (50.0%) 31 (59.6%) 2.451 0.294 NS
Hyperplasia 5 (50.0%) 15 (28.8%)
Thymoma 0 (0.0%) 6 (11.5%)
Other autoimmune Negative 16 (94.1%) 73 (90.1%) 1.819 0.403 NS
Thyrotoxicosis 0 (0.0%) 6 (7.4%)
Systemic lupus 1 (5.9%) 2 (2.5%)
  1. > 0.05 NS, non-significant; < 0.05 S, significant; < 0.01 HS highly significant, TPE therapeutic plasmapheresis, SD standard deviation, AchR acetylcholine receptor
  2. aIndependent t test
  3. bChi-square test